Accuray Incorporated (ARAY)

Market Cap	45.67M -76.1%
Revenue (ttm)	436.97M -3.6%
Net Income	-35.62M
EPS	-0.33
Shares Out	118.78M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	731,301
Open	0.3754
Previous Close	0.3794
Day's Range	0.3700 - 0.3911
52-Week Range	0.3301 - 2.1000
Beta	1.20
Analysts	Strong Buy
Price Target	3.50 (+810.27%)
Earnings Date	Apr 29, 2026

About ARAY

Accuray Incorporated engages in the design, development, manufacture, and sale of radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidne...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Feb 8, 2007
• Employees: 990
• Stock Exchange: NASDAQ
• Ticker Symbol: ARAY
• Website: https://www.accuray.com

Financial Performance

In fiscal year 2025, Accuray's revenue was $458.51 million, an increase of 2.68% compared to the previous year's $446.55 million. Losses were -$1.59 million, -89.77% less than in 2024.

Analyst Summary

According to 2 analysts, the average rating for ARAY stock is "Strong Buy." The 12-month stock price target is $3.5, which is an increase of 810.27% from the latest price.

Price Target

$3.5

(810.27% upside)

Analyst Consensus: Strong Buy